These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 19203530)
41. American Association for Cancer Research--100th Annual Meeting. HDAC inhibitors, proteasome inhibitors and vascular disrupting agents. 18-22 April 2009, Denver, CO, USA. Mitra AP IDrugs; 2009 Jun; 12(6):339-41. PubMed ID: 19517310 [No Abstract] [Full Text] [Related]
42. SRC as a potential therapeutic target in solid tumor oncology. Gallick GE Clin Adv Hematol Oncol; 2004 Jul; 2(7):435-7. PubMed ID: 16163218 [No Abstract] [Full Text] [Related]
44. Translational and clinical studies of target-based cancer therapy. Saijo N; Nishio K; Tamura T Int J Clin Oncol; 2003 Aug; 8(4):187-92. PubMed ID: 12955572 [TBL] [Abstract][Full Text] [Related]
45. Chemistry in cancer research: a vital partnership. Sturla SJ; Irwin JJ; Loeppky RN; Mulvihill MJ; Searcey M ACS Chem Biol; 2007 May; 2(5):286-92. PubMed ID: 17518428 [No Abstract] [Full Text] [Related]
46. Precision Tumor Medicine and Drug Targets. Liu W; Wang X; Zhu H; Duan Y Curr Top Med Chem; 2019; 19(17):1488-1489. PubMed ID: 31592750 [No Abstract] [Full Text] [Related]
47. The role of the National Cancer Institute in drug development. Doroshow J Clin Adv Hematol Oncol; 2005 Apr; 3(4):257-8. PubMed ID: 16166997 [No Abstract] [Full Text] [Related]
48. SOP 07a: Monitoring of a trial under CESAR responsibility. Onkologie; 2003 Oct; 26 Suppl 6():38-40. PubMed ID: 23570184 [No Abstract] [Full Text] [Related]
49. American association for cancer research - 101st annual meeting - investigating new therapeutic candidates: part 2. Mason VL IDrugs; 2010 Jun; 13(6):360-2. PubMed ID: 20506053 [TBL] [Abstract][Full Text] [Related]
50. 'Statistical controversies in clinical research': a new series in Annals of Oncology. Soria JC; Buyse M Ann Oncol; 2015 Aug; 26(8):1532. PubMed ID: 25904726 [No Abstract] [Full Text] [Related]
51. Anticancer drug R&D landscape in China. Zhao S; Zhao H; Lv C; Gong J; Zhang J; Fang W; Li J; Hu X; Ba Y; Xu B; Zhang Y; Fan Y; Li K; Chen X; Yang Z; Shen L; Zhang L J Hematol Oncol; 2020 May; 13(1):51. PubMed ID: 32404176 [No Abstract] [Full Text] [Related]
58. Extended abstracts of the Annual Symposium of the Working Group for Pharmacology in Oncology and Hematology (APOH) of the Central European Society for Anticancer Drug Research (CESAR). June 12-14, 2008. Göttingen, Germany. Int J Clin Pharmacol Ther; 2009 Jan; 47(1):30-64. PubMed ID: 19385009 [No Abstract] [Full Text] [Related]
59. The convergence of cancer prevention and therapy in early-phase clinical drug development. Abbruzzese JL; Lippman SM Cancer Cell; 2004 Oct; 6(4):321-6. PubMed ID: 15488755 [TBL] [Abstract][Full Text] [Related]
60. Antibody-drug conjugates for cancer: poised to deliver? Hughes B Nat Rev Drug Discov; 2010 Sep; 9(9):665-7. PubMed ID: 20811367 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]